登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05528055,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL
入选标准第 1 条
Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
排除标准第 2 条
Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
排除标准第 3 条
ECOG Performance Status 0 or 1.
入选标准第 4 条
History of a second malignancy within 2 years (as defined in the protocol).
排除标准第 5 条
Gestating or Lactating women.
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05528055,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL Relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available. At least one evaluable or measurable lesion (as defined in the protocol). ECOG Performance Status 0 or 1. Life expectancy ≥12 weeks. Adequate organ function (as defined in the protocol). Reproductive criteria (as defined in the protocol).排除标准:Exclusion Criteria:
Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption. Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry. Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ). Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose. History of a second malignancy within 2 years (as defined in the protocol). Active uncontrolled or symptomatic lung disease (as defined in the protocol). Intracranial hypertension or active uncontrolled or symptomatic CNS metastases. Known or suspected hypersensitivity to study medications. Known active uncontrolled or symptomatic CNS metastases. The investigator determined that the patient should not participate in the study. Known mental illness or substance abuse that may disrupt therapy. Clinically significant cardiac abnormalities (as defined in the protocol). Gestating or Lactating women. Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose. The patient is currently using a drug known to be a strong inhibitor or inducer of CYP3A4.
引自 ClinicalTrials.gov, NCT05528055, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05528055,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。